Corporate | 10 June 2003 10:24

Biotest AG english

Biotest sells its shareholding in Envitec Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Biotest sells its shareholding in Envitec Dreieich, 10 June 2003. Biotest has sold its 60% shareholding in Envitec-Wismar GmbH, Wismar, to a holding company formed by LB Kiel Unternehmensbeteiligungsgesellschaft mbH, a subsidiary of HSH-Nordbank AG, and the management of Envitec. This sale is retroactive to 1 January 2003. Both sides have agreed to maintain silence about the retail price. Envitec, based in Wismar, specialises in the development and manufacture of sensors and high quality monitoring equipment for application in the medical, industrial and environment technology sectors. With a 110-strong workforce, Envitec achieved a turnover of EUR 11.8 million and an after-tax result of EUR 0.4 million in 2002. This sale completes Biotests disinvestments in medical technology, in accordance with the companys strategic review and subsequent reorganisation of its business portfolio. As part of the reorganisation, Biotest has already relinquished/sold Biotest Medizintechnik GmbH in Alzenau and Diaclone SAS in Besançon, France. Biotests strategy focuses tightly on its core business – the diagnosis and treatment of immunological disorders and diseases of the haematopoietic system in the human body. This programme of reorganisation will help Biotest enhance its position as a global specialist in the developing areas of immunology and haematology. Biotest AG The Board of Management end of message, (c)DGAP 10.06.2003 ——————————————————————————– WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 101024 Jun 03